Stock NGEN NERVGEN PHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Delayed Toronto S.E.
Other stock markets
 07:23:32 29/04/2024 pm IST 		5-day change 1st Jan Change
2.11 CAD 0.00% Intraday chart for NervGen Pharma Corp. -0.94% -21.85%
17/04 NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update MT
17/04 NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
NervGen Pharma Closes C$23 Million Bought Deal Financing
NervGen Pharma Corp. Plans to Initiate A New Study in Which Subjects Completes Open-Label Nvg-291
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury
Nervgen Pharma Appoints John Ruffolo to Board of Directors
NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Nervgen Pharma Corp. Receives Institutional Review Board Approval for Its Phase 1B/2A Proof-Of-Concept Clinical Trial Protocol of Its Proprietary Lead Compound, Nvg-291, in Individuals with Spinal Cord Injury
NervGen Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
Nervgen Pharma Corp. Appoints Michael Kelly as CEO
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
NervGen Pharma Reports Dosing of All Subjects in Phase 1 Clinical Trial of Drug Candidate NVG-291
NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291
NervGen Pharma Corp. Announces Executive Changes
NervGen Pharma Corp. Announces Executive Changes
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NGEN Stock
  4. News NervGen Pharma Corp.
  5. Other languages